The antidepressant Celexa (generic: citalopram) has been linked to serious side effects, including birth defects in babies whose mothers take the drug during pregnancy.
Update: Healthcare Funds Push for Class-Action Certification in Celexa MDL
May 10, 2016 – Healthcare fund providers seeking to recover money lost because of Forest Laboratories’ allegedly fraudulent promotion of Celexa and Lexapro (generic: escitalopram) in treating pediatric depression pressed a federal judge to certify their portion of the multidistrict litigation (MDL) as a class-action, according to Law360. The private 3rd-party payors, led by Painters and Allied Trades District Council 82 Healthcare Fund, claim they were forced to pay for patients’ use of the antidepressants because of Forest’s allegedly misleading statements about their effectiveness on children.
Celexa Birth Defects
The FDA first approved Celexa in July 1988. The drug quickly became popular in the U.S., and is currently one of the best-selling antidepressants worldwide. Forest Labs marketed Celexa as a safe and effective treatment for mood disorders; however, recent studies have linked it and other similar antidepressants to dangerous side effects, including the following birth defects:
- Atrial Septal Defects (ASD)
- Ventricular Septal Defects (VSD)
- Persistent Pulmonary Hypertension of the Newborn (PPHN)
- Tricuspid Valve (Ebstein’s Anomaly)
- Mitral Valve Prolapse
- Transposition of the Great Arteries (TGA)
- Transposition of the Great Vessels (TGV)
- Tetralogy of Fallot (TOF)
- Hypoplastic Left Heart Syndrome (HLHS)
- Hypoplastic Right Heart Syndrome (HRHS)
- Tricuspid Atresia
- Aortic Stenosis
- Pulmonary Atresia (PA)
- Patent Ductus Arteriosus (PDA)
- Coarctation of the Aorta
- Truncus Arteriosus
- Tricuspid Valve Stenosis
- Heart Murmur
- Pulmonary Stenosis
- Gastroschisis – abdominal wall defect
- Esophageal Stenosis
- Anal Atresia
- Spina Bifida
Has a Celexa Class Action Been Filed?
In March 2014, Forest Labs agreed to pay up to $10.4 million to resolve a multidistrict litigation (MDL) involving Celexa. The complaint accused the company of improperly marketing Celexa “off-label” to children in MO, although it was only approved for use in adults.
Thousands of women who took antidepressants like Celexa during pregnancy have filed lawsuits against drugmakers for failing to warn about the risk of birth defects. These are individual lawsuits which have not been included in a class action.